Codexis Announces Technology Collaboration and License Agreement With GSK

Codexis to Receive Up to $25 Million of Initial Payments, Plus Additional Milestone and Royalty Opportunities
Codexis to Host a Conference Call on July 15, 2014 at 8:30 a.m. ET / 5:30 a.m. PT

REDWOOD CITY, Calif., July 14, 2014 -- Codexis, Inc. (CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, today announced the signing of a platform technology license agreement with GlaxoSmithKline (GSK).

Under the terms of the agreement, Codexis granted GSK a license to use Codexis' proprietary CodeEvolver(R) protein engineering platform technology in the field of human healthcare. The license allows GSK to use Codexis' platform technology to develop novel enzymes for use in the manufacture of GSK's pharmaceutical and health care products.

Progenics Holds Conference Call This Morning on FDA Appeal Response Regarding Relistor(R) sNDA for Patients With Chronic Non-Cancer Pain

TARRYTOWN, N.Y., July 14, 2014 -- Progenics Pharmaceuticals, Inc. (PGNX) chief executive officer Mark Baker will comment on the FDA's Relistor^(R) Appeal Response in a conference call this morning, Monday, July 14, at 8:30 a.m. Eastern Time.

More information concerning the Appeal Response is available in the joint press release issued this morning with the Company's collaboration partner, Salix Pharmaceuticals (SLXP).

Can-Fite's CF102 Approved for Compassionate Use in Israel for Liver Cancer Patient

Patient was previously enrolled in Can-Fite's Phase I/II liver cancer study and has survived for about 5-years using the Company's cancer drug; The global liver cancer drug market is expected to exceed $2 billion by 2015

PETACH TIKVA, Israel, July 10, 2014 -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (CFBI.TA), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that the Israeli Ministry of Health (MOH) has approved the use of its drug CF102 for a patient with hepatocellular carcinoma, the most common form of liver cancer, under the country's Compassionate Use Program. The program allows doctor-initiated single-patient access to investigational treatments for innovative or investigational products not yet registered in any country worldwide.  Can-Fite has also previously received Orphan Drug Designation from the U.S. Food and Drug Administration for CF102 in the treatment of advanced hepatocellular carcinoma.